Marchés
Santacruz Silver posts 55% revenue jump in Q2 2026, AISC falls 24%
Silver miner Santacruz Silver Mining reported $113.46 million in revenue for Q2 2026, up 55% year-over-year, while all-in sustaining costs dropped to $21.87 per ounce. Net income fell to $2 million amid non-cash charges tied to exchange-rate shifts in Bolivia.
ARK ETFs shift holdings: buys BWX Technologies, sells Roblox and Shopify
ARK Investment Management executed trades on Aug. 20, adding stakes in BWX Technologies and four other firms while trimming positions in Roblox, Shopify and 10X Genomics.
China’s tech trio diverges in Q2 2026: Tencent rises, Alibaba and Baidu miss
Tencent beats estimates for a fourth straight quarter, while Alibaba and Baidu miss margins. Earnings, margins and valuations highlight stark divergence among China’s largest internet stocks.
USD/CHF bears regain control as Swiss franc draws haven flows
U.S. Treasury’s expanded long-end buybacks and shifting correlations fuel safe-haven demand for the franc, pushing USD/CHF below key support. Technicals and fundamentals suggest further downside if resistance holds.
Graubündner Kantonalbank posts record H1 profit as revenue rises 11%
Swiss regional lender reports CHF 137.2 million net income for the first half of 2025, driven by broad-based growth in interest and fee income. CET1 ratio climbs to 20.2%.
Swiss nuclear plant costs estimated at $14-43 bln in new study
A report by Swiss Academies of Sciences estimates construction costs for a new nuclear reactor between 14 billion and 43 billion francs, factoring in delays and financing risks. State support likely required.
Siegfried maintains 2026 outlook after 2H gains from U.S., Australia sites
Swiss pharma services group posts 2.2% H1 sales growth to 633M CHF; core EBITDA margin rises to 22.4%. Three newly acquired sites expected to add $100M in 2026 revenue.
Anthropic IPO plans, Nvidia earnings test AI trade as tech stocks slip
Anthropic is preparing to file for a public listing by month-end, targeting a valuation above SpaceX's $75 billion IPO. Nvidia's earnings next week will further shape AI sector sentiment.
Calendrier économique suisse : résultats du 2e trimestre, données macroéconomiques du 21 au 28 août
Les investisseurs affronteront une semaine chargée de résultats semestriels suisses, de résultats du deuxième trimestre et d'indicateurs macroéconomiques clés, notamment le PIB, le tourisme et les données sur l'emploi.
Lifestyle Communities posts FY26 turnaround with AUD 186.8m debt cut
Net debt fell 40.6% to AUD 273.7m as operating cash flow swung to AUD 94.9m. Shares rose 1.7% after FY26 profit after tax reached AUD 46.9m.
Sika vend 1 milliard d'euros de titres hybrides à des investisseurs européens
Le groupe suisse de produits chimiques de spécialité place des obligations 30NC5.75 et 30NC8.75 à des rendements de 4,50 % et 5,00 %, respectivement, avec S&P attribuant 50 % de crédit d'équité.
MAAS Group posts 37% EBITDA rise, lifts buyback plan to 20% of shares
Underlying EBITDA surged 37% to AUD 300.3 million in H2 2026, while revenue climbed 27% to AUD 1.3 billion. The group expanded its buyback program to 20% of issued capital over 12 months.
Les actions de CSL progressent de 3,3 % après les résultats de l'exercice 26 et l'annonce d'un rachat d'actions
Le titre de la société australienne CSL progressait pour une deuxième journée, alors que les investisseurs digéraient des résultats plus performants que prévu et un programme de rachat d’actions de 1,1 milliard de dollars australiens. Les courtiers ont relevé leurs cibles de prix suite aux résultats de l’exercice 26.
Super Retail FY26 sales rise to $4.2bn as profit slips on transformation costs
Australia’s Super Retail Group posted record annual sales but normalized profit fell 7% as higher transformation costs weighed on margins. Shares surged 15.3% on the update.
Sonic Healthcare posts 13% revenue rise but shares drop on FY2026 outlook
Australia’s largest pathology provider reported A$10.9 billion in revenue for FY2026, up 13% year-over-year, but its stock fell 9.2% after missing earnings expectations and flagging margin pressures in key markets.
Emeco’s FY26 results show maintenance shift boosts returns, buyback approved
Emeco Holdings reported a 5% rise in FY26 net profit as maintenance services drove revenue growth, while the board greenlit a 10% share buyback. Net debt fell to $127.1 million.
ASP Isotopes outlines commercialization roadmap at Emerging Growth Conference
CEO Paul Mann details multi-phase expansion plans for helium, LNG, and medical isotopes, targeting $300 million EBITDA by 2031. Stock has fallen 73% from 52-week high.
Optimism shifts 546.9M OP tokens from airdrops to ecosystem fund
Governance proposal reallocates tokens to drive institutional adoption and network growth, despite opposition over unfulfilled user promises.
Emeco targets 20% ROC with $127.6m FY26 free cash flow
Australia’s largest mining equipment renter posts 16.9% return on capital, approves 10% buyback after FY26 results. Maintenance revenue now 50% of gross.
Codan posts 69% profit surge on defence, gold detector demand
ASX-listed Codan reported FY26 net profit of $175.2m, up 69% YoY, as defence and metal detection revenues surged. Shares rose 11.8% to $48.61.
Brambles FY26 profit hit by U.S. repair constraints, recovery plan outlined
Underlying profit rose 4% to $1.49 billion despite $90 million hit from U.S. repair bottlenecks, with a $25 million repair expansion plan set for FY28. Dividend maintained at 46.15 cents per share.
Goodman Group posts 10.1% FY2026 profit rise, targets 9% FY2027 EPS growth
Australia’s industrial and data center specialist Goodman Group reported a 10.1% jump in FY2026 operating profit to AUD 2.675 billion and set a 9% EPS growth target for FY2027. The group’s data center pipeline surged to AUD 19.7 billion.
Wolfspeed shares plunge 9% after weak earnings miss, guidance cut
Silicon carbide chipmaker reports adjusted loss of $2.26 per share, missing estimates by over 400%, as revenue falls 28% short of forecasts.
Novartis to present cardiovascular data at ESC Congress 2026
Ten abstracts across Novartis's cardiovascular portfolio will highlight Leqvio, abelacimab and Entresto, including late-breaking Phase IV trial results and Lp(a) testing strategies.
Merck, Moderna cancer vaccine trial shows 59% reduction in recurrence risk
Merck and Moderna’s mRNA cancer vaccine cut melanoma recurrence risk by 59% in late-stage trial, signaling a potential shift in oncology treatment. Data released Wednesday underscores the promise of personalized mRNA therapies.